MPS-215

MPS-215 is a small molecule tyrosine kinase inhibitor (TKI) that selectively targets the MET receptor (Hepatocyte Growth Factor Receptor, HGFR). Developed by the Fondazione Ricerca Traslazionale (FoRT), it is primarily investigated for the treatment of advanced solid tumors, with a specific focus on non-small cell lung cancer (NSCLC) characterized by MET alterations, such as amplification or exon 14 skipping mutations. MET signaling is a critical driver of oncogenesis and a frequent mechanism of acquired resistance to EGFR inhibitors like osimertinib. By binding to the MET kinase domain, MPS-215 inhibits downstream signaling pathways, including PI3K/AKT and MAPK/ERK, thereby suppressing tumor cell proliferation, survival, and epithelial-to-mesenchymal transition (EMT).